Eosinophilic Phenotype

FDA approves Dupixent for COPD with eosinophilic phenotype

The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.